Clinical trial · Interventional

Semaglutide and Polycystic Ovarian Syndrome: an Emerging Treatment Strategy

NCT06222437CI-TRIAL-00106269withdrawnPhase 1ClinicalTrials.gov clinicaltrialsPublishedExplore in graph →

Why stopped (as posted): IRB did not approve

Summary

Brief summary (as posted)

The purpose of this study is to investigate the effect of semaglutide in women with Polycystic Ovarian Syndrome(PCOS ) and determine potential therapeutic benefits.

Conditions

Conditions (1)

Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.

Condition (as posted)	Mapped entity	Match	Confidence
Polycystic Ovary Syndrome	—	UNRESOLVED	—

Interventions

Interventions (1)

Intervention	Type	Mapped drug	Match
Semaglutide	Drug	—	UNRESOLVED

Design

Arms and outcomes

Arms (1)

type
EXPERIMENTAL
label
Protocol group
description
PCOS women in the age 18 to 45 years
interventionNames
1. Drug: Semaglutide

Primary outcomes (2)

measure
Number of appropriate weekly dose
timeFrame
4 weeks
description
To access the compliances of the therapy
measure
Number of days on therapy
timeFrame
4 weeks
description
To access the persistence on Semaglutide

Secondary outcomes (2)

Eligibility

Eligibility (as posted)

Sex: Female
Minimum age: 18 Years
Maximum age: 45 Years

Show eligibility criteria text

Inclusion Criteria:

* Age 18-45
* Body mass index(BMI) \> 30
* Diagnosis of PCOS
* Normal thyroid stimulating hormone, prolactin, follicle-stimulating hormone (FSH), estradiol, and normal progesterone

Exclusion Criteria:

* Medications excluded: any hormone-containing contraceptive - oral contraceptive pills, Progesterone-only pill, depo-provera, oral provera, progesterone-containing intrauterine contraceptive device
* Letrozole, clomiphene citrate, FSH therapy
* Androgen receptor blockers
* 5α reductase inhibitors
* Insulin
* Hysterectomy
* Endometrial ablation

References

Publications (0)

Data not yet available

No reference posted for this study.